Skip to main content
. 2020 Oct 31;6(6):364–372. doi: 10.1007/s40495-020-00243-4

Table 2.

Data compilation of CQ and HCQ myopathy based in the literature review from 1963 to April/2020

Data Values n
Age (year) 59(M) 56
59 (Med)
28–89
G (F)% 73.2 56
Underlying disease (%)
  RA 42.8 56
  SLE 26.8
  ORD 17.8
  Misc 12.6
Drug %
  CQ 58.9 56
  HQC 41
  DD(mg/d) 393(M) 56
400(Med)
  DT(m) 37(QC) 56
24(HCQ)
  PW/CW/Dys (%) 87.2/17.8/8.9 56
  Elevated CK %/M/Med 60.7/613/339 34
  RD % 12.5 56
EMG %
  Myop 54 50
  Neuromyo 16
  N 2
Muscle biopsy %
  Vacuolar 53.7 54
  NSF 46.2
MB (EM) %
  CB 86.8 38
  MB 8
  Impr/death (%) 85.4/12.7 55

M, mean; Med, median; y, year; G, gender; F, female; CQ, chloroquine; HCQ, hydroxychloroquine; DD, daily dose; DT, duration treatment; m, months; PW, proximal weakness; CW, cervical weakness; Dys, dysphagia; OM, optic microscopy; EM, electron microscopy; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; ORD, other rheumatic diseases; Misc, miscellaneous; CQ, chloroquine; HQC ORD, other rheumatic disorders; CK, creatine kinase; RD, respiratory distress; Myop, myopathic; Neuromyo, neuromyopathic; N, neuropathy; NSF, no specific findings; CB, curvilinear bodies; MB, myeloid bodies; Impr, improvement